Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Incidence of Gastrointestinal stromal tumor
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Gastrointestinal stromal tumor

1 evidence topic · 2 sources

U.S. epidemiology

“Annual age-adjusted incidence rose from 0.55/100,000 in 2001 to 0.78/100,000 in 2011 and increased with age, peaking among 70-79 year olds (3.06/100,000).” (opens the source at this quote in a new tab)